Matt Berry, associate analyst at John McCamant's Medical Technology Stock Letter, says much of the malaise in the current market is fallout from the ImClone (nasdaq: IMCL - news - people ) fiasco.

FORBES: Will Biotech Boom Again?

Associated Press writers Bridget Murphy and Bob Salsberg in Boston, Lynn Berry in Moscow, and Kimberly Dozier, Adam Goldman, Eric Tucker, Matt Apuzzo, and Eileen Sullivan in Washington contributed to this report.

NPR: Boston Bomb Investigation Extends To Russia